Lead-Oriented Synthesis: Exploring Drug-Relevant Chemical Diversity


Lead-Oriented Synthesis: Exploring Drug-Relevant Chemical Diversity

Friday 25 September
GSK Stevenage

The ready availability of structurally novel lead molecules with appropriately controlled molecular properties (e.g. logP, molecular weight and fraction of sp3 atoms) is crucial to the ability of the pharmaceutical industry to bring new small molecule drugs to market. However, it is now recognised that access to such lead molecules is poorly served not only by many current commercial libraries but also by the synthetic methods widely adopted within industry and many of those developed in academic laboratories. In this meeting, approaches to rectifying this issue will be presented both from academia and industry, with the hope of stimulating a broader recognition of, and solutions to, the challenges of lead-oriented synthesis.

Meeting report: open in a new window


09:45 Registration and coffee
10:30 Welcome and housekeeping
Prof. Adam Nelson (University of Leeds)
10:40 How synthetic chemistry can drive the discovery of drugs of the future
Dr Ian Churcher (GSK)
11:00 Exploring 3D pharmaceutical space: lead-oriented and fragment-oriented synthesis 
Prof. Peter O’Brien (University of York)
11:40 LLAMA: An open-access tool to guide lead-oriented synthesis
Prof. Adam Nelson (University of Leeds) & Dr Richard Doveston (TU Eindhoven)
12:00 Lunch and freeware demonstration
13:15 Synthetic strategies for the efficient exploration of lead-like space
Prof. Steve Marsden (University of Leeds)
13:55 Design and exploitation of novel medicinal chemistry reagent sets
Dr Jason Kettle (AstraZeneca)
14:35 Enriching chemical space to drug undruggable targets
Prof. David Spring (University of Cambridge)
15:15 Afternoon refreshments
15:45 Cross coupling 2.0
Prof Jeffrey Bode (ETH Zurich)
16:45 Concluding remarks and close of meeting

Organising Committee: Prof Steve Marsden & Prof Adam Nelson